These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31565761)

  • 21. Approaches to Aggregation and Decision Making-A Health Economics Approach: An ISPOR Special Task Force Report [5].
    Phelps CE; Lakdawalla DN; Basu A; Drummond MF; Towse A; Danzon PM
    Value Health; 2018 Feb; 21(2):146-154. PubMed ID: 29477392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comment on: 'The cost of a QALY'.
    Adam J; Stevens A
    QJM; 2011 Mar; 104(3):272-3. PubMed ID: 21030464
    [No Abstract]   [Full Text] [Related]  

  • 23. Evidence-based decision-making 3: Health technology assessment.
    O'Reilly D; Campbell K; Vanstone M; Bowen JM; Schwartz L; Assasi N; Goeree R
    Methods Mol Biol; 2015; 1281():417-41. PubMed ID: 25694325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The NICE reference case requirement: implications for drug manufacturers and health systems.
    Langley PC
    Pharmacoeconomics; 2004; 22(4):267-71. PubMed ID: 14974876
    [No Abstract]   [Full Text] [Related]  

  • 25. Health technology assessment in the United Kingdom.
    Akehurst R
    Value Health; 2010 Jun; 13 Suppl 1():S4-5. PubMed ID: 20618794
    [No Abstract]   [Full Text] [Related]  

  • 26. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 27. Evidence-based decision making in healthcare in Central Eastern Europe.
    Ferrario A; Baltezarević D; Novakovic T; Parker M; Samardzic J
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):611-5. PubMed ID: 25090222
    [No Abstract]   [Full Text] [Related]  

  • 28. HTA Around the World: Broadening Our Understanding of Cross-Country Differences.
    Torbica A
    Value Health; 2020 Jan; 23(1):1-2. PubMed ID: 31952663
    [No Abstract]   [Full Text] [Related]  

  • 29. An introduction to the methods of cost-effectiveness analysis.
    Drug Ther Bull; 2012 Jul; 50(7):81-4. PubMed ID: 22789768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of technology assessment in health benefits coverage for medical devices.
    Braslow NM; Shatin D; McCarthy DB; Newcomer LN
    Am J Manag Care; 1998 Sep; 4 Spec No():SP139-50. PubMed ID: 10185990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health Technology Assessment and Appraisal of Therapies for Rare Diseases.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Adv Exp Med Biol; 2017; 1031():221-231. PubMed ID: 29214575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TESTING MULTI-CRITERIA DECISION ANALYSIS FOR MORE TRANSPARENT RESOURCE-ALLOCATION DECISION MAKING IN COLOMBIA.
    Castro Jaramillo HE; Goetghebeur M; Moreno-Mattar O
    Int J Technol Assess Health Care; 2016 Jan; 32(4):307-314. PubMed ID: 27691990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health care technology in France.
    Weill C
    Health Policy; 1994; 30(1-3):123-62. PubMed ID: 10139489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
    Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
    Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 'Health Economics' and the evolution of economic evaluation of health technologies.
    Hutton J
    Health Econ; 2012 Jan; 21(1):13-8. PubMed ID: 22147623
    [No Abstract]   [Full Text] [Related]  

  • 36. HEALTH TECHNOLOGY ASSESSMENT IN CENTRAL, EASTERN, AND SOUTH EUROPEAN COUNTRIES: CROATIA.
    Huic M; Tandara Hacek R; Svajger I
    Int J Technol Assess Health Care; 2017 Jan; 33(3):376-383. PubMed ID: 28803589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An equity framework for health technology assessments.
    Culyer AJ; Bombard Y
    Med Decis Making; 2012; 32(3):428-41. PubMed ID: 22065143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
    Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
    Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A determination of topics for health technology assessment in Thailand: making decision makers involved.
    Lertpitakpong C; Chaikledkaew U; Thavorncharoensap M; Tantivess S; Praditsitthikorn N; Youngkong S; Yothasamut J; Udomsuk K; Sinthitichai K; Teerawattananon Y
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S100-9. PubMed ID: 19253492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HARMONIZING HEALTH TECHNOLOGY ASSESSMENT PRACTICES IN UNIVERSITY HOSPITALS: TO WHAT EXTENT IS THE MINI-HTA MODEL SUITABLE IN THE FRENCH CONTEXT?
    Martelli N; Devaux C; van den Brink H; Billaux M; Pineau J; Prognon P; Borget I
    Int J Technol Assess Health Care; 2017 Jan; 33(2):307-314. PubMed ID: 28580892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.